Feedback / Questions
Semprana (dihydroergotamine oral inhalation) - AbbVie
MAP Pharma: J.P. Morgan Healthcare Conference
(MAP Pharmaceuticals)
-
Feb 1, 2013 -
"FREEDOM-301: Met All Four Co-Primary Endpoints"; AE's reported by at least 2% of LEVADEX patients and greater than placebo"
P3 data
•
Migraine
http://files.shareholder.com/downloads/MAPP/2298852646x0x626871/C8A582E2-D9E9-4C17-906D-C46BD2389D74/MAPP_JAN_2013_JPM.pdf
Feb 1, 2013
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious